MLYS: Lorundrostat prepares for launch with strong clinical data, parity access strategy, and full funding
Lorundrostat is advancing toward a December PDUFA date, supported by robust clinical data and a comprehensive commercial build-out targeting third- and fourth-line hypertension. The launch strategy emphasizes parity access, broad prescriber reach, and ongoing R&D, with full funding secured through…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.